Nierenzellkarzinom beim alten und geriatrischen Patienten

Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Das Nierenzellkarzinom des alten und geriatrischen Patienten erfordert eine Adaptation der klassischen therapeutischen Strategien. Das Management sollte hierbei individuell an Alter und Komorbiditäten angepasst und die Effektivität und Risiken bzw. Toxizität aller therapeutischen Optionen überlegt werden. Ein multidisziplinäres Vorgehen von erfahrenen Urologen, Onkologen, Nephrologen, Radiologen, Pathologen, Strahlentherapeuten und ggf. Geriatern, Schmerztherapeuten und Palliativmedizinern ist wichtig für Diagnose, Assessment und Therapiewahl. Die Empfehlungen sollten mit den einzelnen Patienten und wenn möglich ihren Angehörigen auf die individuellen Bedürfnisse hin diskutiert und eine zu Patientenpräferenzen passende Entscheidung getroffen werden.

Literatur

  1. Abouassaly R, Yang S, Finelli A, Kulkarni GS, Alibhai SM (2011a) What is the best treatment strategy for incidentally detected small renal masses? A decision analysis. BJU Int 108(8 Pt 2):E223–E231.  https://doi.org/10.1111/j.1464-410X.2011.10115.xPubMedGoogle Scholar
  2. Abouassaly R, Alibhai SM, Tomlinson GA, Urbach DR, Finelli A (2011b) The effect of age on the morbidity of kidney surgery. J Urol 186(3):811–816.  https://doi.org/10.1016/j.juro.2011.04.077PubMedGoogle Scholar
  3. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13):2873–2882.  https://doi.org/10.1002/cncr.25836PubMedGoogle Scholar
  4. Beck J, Procopio G, Bajetta E, Keilholz U, Negrier S, Szczylik C, Bokemeyer C, Bracarda S, Richel DJ, Staehler M, Strauss UP, Mersmann S, Burock K, Escudier B (2011) Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol 22(8):1812–1823.  https://doi.org/10.1093/annonc/mdq651PubMedGoogle Scholar
  5. Bellmunt J, Négrier S, Escudier B, Awada A, Aapro M, Taskforce SIOG (2009) The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol 69(1):64–72.  https://doi.org/10.1016/j.critrevonc.2008.08.002PubMedGoogle Scholar
  6. Benson AB 3rd, Pregler JP, Bean JA, Rademaker AW, Eshler B, Anderson K (1991) Oncologists’ reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol 9(11):2067–2075PubMedGoogle Scholar
  7. Berger J, Fardoun T, Brassart E, Capon G, Bigot P, Bernhard JC, Rigaud J, Patard JJ, Descazeaud A (2012) Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians. J Urol 188(3):736–740.  https://doi.org/10.1016/j.juro.2012.05.008PubMedGoogle Scholar
  8. Best SL, Park SK, Youssef RF, Olweny EO, Tan YK, Trimmer C, Cadeddu JA (2012) Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters. J Urol 187(4):1183–1189.  https://doi.org/10.1016/j.juro.2011.11.096PubMedGoogle Scholar
  9. Brom RR van den, van Es SC, Leliveld AM, Gietema JA, Hospers GA, de Jong IJ, de Vries EG, Oosting SF (2016) Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. Cancer Treat Rev 46:63–72.  https://doi.org/10.1016/j.ctrv.2016.04.002
  10. Cloutier V, Capitanio U, Zini L, Perrotte P, Jeldres C, Shariat SF, Arjane P, Patard JJ, Montorsi F, Karakiewicz PI (2009) Thirty-day mortality after nephrectomy: clinical implications for informed consent. Eur Urol 56(6):998–1003.  https://doi.org/10.1016/j.eururo.2008.11.023PubMedGoogle Scholar
  11. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 52(12):1131–1136PubMedGoogle Scholar
  12. Cohen HT, McGovern FJ (2005) Renal-cell carcinoma. N Engl J Med 353(23):2477–2490PubMedGoogle Scholar
  13. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P (2008) Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol 180(3):873–878.  https://doi.org/10.1016/j.juro.2008.05.006; discussion 878PubMedPubMedCentralGoogle Scholar
  14. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B, TARGET Study Group (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100(20):1454–1463.  https://doi.org/10.1093/jnci/djn319PubMedPubMedCentralGoogle Scholar
  15. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A, ESMO Guidelines Working Group (2014) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii49–iii56.  https://doi.org/10.1093/annonc/mdu259. Erratum in: Ann Oncol. 2015 Sep;26 Suppl 5:v174-177PubMedGoogle Scholar
  16. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345(23):1655–1659PubMedGoogle Scholar
  17. González León T, Morera Pérez M (2016) Renal cancer in the elderly. Curr Urol Rep 17(1):6.  https://doi.org/10.1007/s11934-015-0562-2PubMedGoogle Scholar
  18. Hellenthal NJ, Mansour AM, Hayn MH, Schwaab T (2011) Renal cell carcinoma in octogenarians: nephron sparing surgery should remain the standard of care. J Urol 185(2):415–420.  https://doi.org/10.1016/j.juro.2010.09.071PubMedGoogle Scholar
  19. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799.  https://doi.org/10.1200/JCO.2008.21.4809PubMedGoogle Scholar
  20. Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA, Barrios CH, Escudier B, Lin X, Fly K, Martell B, Matczak E, Motzer RJ (2014) Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer 110(5):1125–1132.  https://doi.org/10.1038/bjc.2013.832PubMedPubMedCentralGoogle Scholar
  21. Jewett MA, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemens DR, Tanguay S, Rendon RA, Gleave ME, Drachenberg DE, Chow R, Chung H, Chin JL, Fleshner NE, Evans AJ, Gallie BL, Haider MA, Kachura JR, Kurban G, Fernandes K, Finelli A (2011) Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 60(1):39–44.  https://doi.org/10.1016/j.eururo.2011.03.030PubMedGoogle Scholar
  22. Johnson S, Pham KN, See W, Begun FP, Langenstroer P (2014) Laparoscopic cryoablation for clinical stage T1 renal masses: long-term oncologic outcomes at the Medical College of Wisconsin. Urology 84(3):613–618.  https://doi.org/10.1016/j.urology.2014.03.055PubMedGoogle Scholar
  23. Johnson DC, Vukina J, Smith AB, Meyer AM, Wheeler SB, Kuo TM, Tan HJ, Woods ME, Raynor MC, Wallen EM, Pruthi RS, Nielsen ME (2015) Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. J Urol 193(1):30–35.  https://doi.org/10.1016/j.juro.2014.07.102PubMedGoogle Scholar
  24. Kader AK, Tamboli P, Luongo T, Matin SF, Bell K, Jonasch E, Swanson DA, Wood CG (2007) Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol 177(3):855–860; discussion 860–861PubMedGoogle Scholar
  25. Karakiewicz PI, Jeldres C, Suardi N, Hutterer GC, Perrotte P, Capitanio U, Ficarra V, Cindolo L, de La Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Schips L, Chautard D, Valeri A, Lechevallier E, Descots JL, Lang H, Mejean A, Verhoest G, Patard JJ (2008) Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J 2(6):610–617PubMedPubMedCentralGoogle Scholar
  26. Kouba E, Smith A, McRackan D, Wallen EM, Pruthi RS (2007) Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J Urol 177(2):466–470; discussion 470PubMedGoogle Scholar
  27. Kunkle DA, Egleston BL, Uzzo RG (2008) Excise, ablate or observe: the small renal mass dilemma – a meta-analysis and review. J Urol 179(4):1227–1233.  https://doi.org/10.1016/j.juro.2007.11.047; discussion 1233–1234PubMedGoogle Scholar
  28. Kutikov A, Egleston BL, Canter D, Smaldone MC, Wong YN, Uzzo RG (2012) Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol 188(6):2077–2083.  https://doi.org/10.1016/j.juro.2012.07.100PubMedPubMedCentralGoogle Scholar
  29. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC (2008) Renal mass biopsy – a renaissance? J Urol 179(1):20–27PubMedGoogle Scholar
  30. Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT, Kaouk JH, Gill IS, Campbell SC (2010) Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 116(13):3119–3126.  https://doi.org/10.1002/cncr.25184PubMedGoogle Scholar
  31. Larcher A, Fossati N, Mistretta F, Lughezzani G, Lista G, Dell'Oglio P, Abrate A, Sun M, Karakiewicz P, Suardi N, Lazzeri M, Montorsi F, Guazzoni G, Buffi N (2015) Long-term oncologic outcomes of laparoscopic renal cryoablation as primary treatment for small renal masses. Urol Oncol 33(1):22.e1–9.  https://doi.org/10.1016/j.urolonc.2014.09.003Google Scholar
  32. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2015) Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 1.0, AWMF Registernummer: 043/017OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html. Zugegriffen am 26.08.2016
  33. Ljungberg B, Bex A, Canfield S, Giles RH, Hora M, Kuczyk MA, Lam T, Merseburger AS, Powles T, Staehler M, Volpe A, EAU Renal Cell Cancer Guidelines (2016) In: Dabestani A, Fernández-Pello Montes S, Hofmann F, Marconi L, Tahbaz R (Guidelines Associates) EAU Renal cell cancer guidelines. EAU Guidelines Office, ArnhemGoogle Scholar
  34. Ma Y, Bedir S, Cadeddu JA, Gahan JC (2014) Long-term outcomes in healthy adults after radiofrequency ablation of T1a renal tumours. BJU Int 113(1):51–55.  https://doi.org/10.1111/bju.12366PubMedGoogle Scholar
  35. Martínez-Salamanca JI, Huang WC, Millán I, Bertini R, Bianco FJ, Carballido JA, Ciancio G, Hernández C, Herranz F, Haferkamp A, Hohenfellner M, Hu B, Koppie T, Martínez-Ballesteros C, Montorsi F, Palou J, Pontes JE, Russo P, Terrone C, Villavicencio H, Volpe A, Libertino JA, International Renal Cell Carcinoma-Venous Thrombus Consortium (2011) Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol 59(1):120–127.  https://doi.org/10.1016/j.eururo.2010.10.001PubMedGoogle Scholar
  36. Mason RJ, Abdolell M, Trottier G, Pringle C, Lawen JG, Bell DG, Jewett MA, Klotz L, Rendon RA (2011) Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol 59(5):863–867.  https://doi.org/10.1016/j.eururo.2011.02.023PubMedGoogle Scholar
  37. Maute L, Bergmann L (2016) Systemic therapy of metastatic renal cell carcinoma. Dtsch Med Wochenschr 141(7):466–469.  https://doi.org/10.1055/s-0042-104594. http://www.ncbi.nlm.nih.gov/pubmed/27031198. Zugegriffen im Oktober 2016
  38. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286):966–970PubMedGoogle Scholar
  39. Miller AJ, Kurup AN, Schmit GD, Weisbrod AJ, Boorjian SA, Thompson RH, Lohse CM, Kor DJ, Callstrom MR, Atwell TD (2015) Percutaneous clinical T1a renal mass ablation in the octogenarian and nonagenarian: oncologic outcomes and morbidity. J Endourol 29(6):671–676.  https://doi.org/10.1089/end.2014.0733PubMedGoogle Scholar
  40. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296PubMedGoogle Scholar
  41. O'Connor KM, Davis N, Lennon GM, Quinlan DM, Mulvin DW (2009) Can we avoid surgery in elderly patients with renal masses by using the Charlson comorbidity index? BJU Int 103(11):1492–1495.  https://doi.org/10.1111/j.1464-410X.2008.08275.xPubMedGoogle Scholar
  42. Patard JJ, Rodriguez A, Rioux-Leclercq N, Guillé F, Lobel B (2002) Prognostic significance of the mode of detection in renal tumours. BJU Int 90(4):358–363PubMedGoogle Scholar
  43. Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, Wagner AA, McKiernan JM, Allaf ME (2015) Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol 68(3):408–415.  https://doi.org/10.1016/j.eururo.2015.02.001PubMedGoogle Scholar
  44. Porta C, Calvo E, Climent MA, Vaishampayan U, Osanto S, Ravaud A, Bracarda S, Hutson TE, Escudier B, Grünwald V, Kim D, Panneerselvam A, Anak O, Motzer RJ (2012) Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 61(4):826–833.  https://doi.org/10.1016/j.eururo.2011.12.057PubMedPubMedCentralGoogle Scholar
  45. Revenig LM, Canter DJ, Taylor MD, Tai C, Sweeney JF, Sarmiento JM, Kooby DA, Maithel SK, Master VA, Ogan K (2013) Too frail for surgery? Initial results of a large multidisciplinary prospective study examining preoperative variables predictive of poor surgical outcomes. J Am Coll Surg 217(4):665–670.e1.  https://doi.org/10.1016/j.jamcollsurg.2013.06.012PubMedGoogle Scholar
  46. Robert-Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (2012) Krebs in Deutschland 2007/2008., G.d.e. K.i.D.e. V. Robert-Koch-Institut, BerlinGoogle Scholar
  47. Rübben H, Heß J (2016) Einführung in die geriatrische Urologie. In: Michel MS, Thüroff JW, Janetschek G, Wirth MP (Hrsg) Die Urologie. Springer, Heidelberg, S 2253–2260Google Scholar
  48. Scoll BJ, Wong YN, Egleston BL, Kunkle DA, Saad IR, Uzzo RG (2009) Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol 181(2):506–511.  https://doi.org/10.1016/j.juro.2008.10.026PubMedGoogle Scholar
  49. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30.  https://doi.org/10.3322/caac.21332PubMedGoogle Scholar
  50. Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, Jewett MA, Greenberg RE, Uzzo RG (2012) Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 4:997–1006.  https://doi.org/10.1002/cncr.26369Google Scholar
  51. Spencer G (1989) Projections of the population of the United States by age, sex and race 1988–2080. In: Current population reports. US Government Printing Office, Washington DC, Series S. 25 no 1018Google Scholar
  52. Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Tian Z, Shariat SF, Widmer H, Zorn K, Menon M, Montorsi F, Perrotte P, Karakiewicz PI (2011) A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. Eur Urol 60(6):1152–1159.  https://doi.org/10.1016/j.eururo.2011.07.064PubMedGoogle Scholar
  53. Sun M, Abdollah F, Schmitges J, Bianchi M, Tian Z, Shariat SF, Zorn K, Pharand D, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI (2012) Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA. BJU Int 109(12):1807–1812.  https://doi.org/10.1111/j.1464-410X.2011.10569.xPubMedGoogle Scholar
  54. Sun M, Bianchi M, Trinh QD, Hansen J, Abdollah F, Hanna N, Tian Z, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI (2013) Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU Int 111(1):67–73.  https://doi.org/10.1111/j.1464-410X.2012.11254.xPubMedGoogle Scholar
  55. Surbone A, Kagawa-Singer M, Terret C, Baider L (2007) The illness trajectory of elderly cancer patients across cultures: SIOG position paper. Ann Oncol 18(4):633–638PubMedGoogle Scholar
  56. Tan HJ, Filson CP, Litwin MS (2015) Contemporary, age-based trends in the incidence and management of patients with early-stage kidney cancer. Urol Oncol 33(1):21.e19–26.  https://doi.org/10.1016/j.urolonc.2014.10.002Google Scholar
  57. Thürmann P (2016) Medikamentöse Therapie im Alter – spezielle Aspekte der Urologie. In: Michel MS, Thüroff JW, Janetschek G, Wirth MP (Hrsg) Die Urologie. Springer, Heidelberg, S 2281–2288Google Scholar
  58. Vetterlein MW, Jindal T, Becker A, Regier M, Kluth LA, Tilki D, Chun FK (2016) Small renal masses in the elderly: contemporary treatment approaches and comparative oncological outcomes of nonsurgical and surgical strategies. Investig Clin Urol 57(4):231–239.  https://doi.org/10.4111/icu.2016.57.4.231PubMedPubMedCentralGoogle Scholar
  59. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA (2004) The natural history of incidentally detected small renal masses. Cancer 100(4):738–745PubMedGoogle Scholar
  60. Volpe A, Finelli A, Gill IS, Jewett MA, Martignoni G, Polascik TJ, Remzi M, Uzzo RG (2012) Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 62(3):491–504.  https://doi.org/10.1016/j.eururo.2012.05.009PubMedGoogle Scholar
  61. Wedding U (2016) Geriatrisches Assessment in der Urologie. In: Michel MS, Thüroff JW, Janetschek G, Wirth MP (Hrsg) Die Urologie. Springer, Heidelberg, S 2273–2280Google Scholar
  62. Zini L, Perrotte P, Jeldres C, Capitanio U, Duclos A, Jolivet-Tremblay M, Arjane P, Péloquin F, Pharand D, Villers A, Montorsi F, Patard JJ, Karakiewicz PI (2009) A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. BJU Int 103(7):899–904.  https://doi.org/10.1111/j.1464-410X.2008.08247.x; discussion 904PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Zentrum für Urologische Tumorerkrankungen, Klinik für UrologieUniversitätsmedizin MannheimMannheimDeutschland

Section editors and affiliations

  • Nicolai Härtel
    • 1
  1. 1.Interdisziplinäres TumorzentrumUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations